Department of Radiation Oncology,Cancer Hospital (Institute),Chinese Academy of Medical Sciences,Peking Union Medical College,Beijing 100021,China Corresponding authors:Jin Jing,Email:jingjin1025@163.com;LiYexiong,Email:yexiong@yahoo.com
Abstract：Objective To investigate the value of postoperative adjuvant chemoradiotherapy (CRT) in the treatment of stage II/III upper rectal cancer. Methods A total of 3995 patients with rectal cancer were admitted to our hospital from 2000 to 2010. Among them, patients who were pathologically diagnosed with adenocarcinoma and underwent radical surgery were enrolled as subjects for retrospective analyses. Moreover, all selected patients had the lower margin of the tumor located within 10-16 cm from the anal verge, as determined by a colonofiberscope before surgery, and were pathologically staged as T3-4 or N0-2M0 after surgery, according to the 7th edition of American Joint Committee on Cancer tumor-node-metastasis staging system. Results A total of 547 patients were enrolled as subjects. The 5-year sample size was 249. In all patients, the 5-year overall survival (OS), disease-free survival, local recurrence-free survival (LRFS), and distant metastasis-free survival rates were 79.0%, 76.8%, 94.0%, and 80.1%, respectively. One hundred and fifty-five patients were enrolled into either postoperative concurrent CRT group or postoperative non-CRT group, with the baseline characteristics balanced between the two groups by the propensity-score matching method (1∶1). Patients who were staged as pT4b and had paracancerous nodules and lymph node metastases (stage N2) were enrolled into high-risk group. In the high-risk group, patients treated with postoperative CRT had significantly higher LRFS and OS rates than those treated with only surgery (96.3% vs. 82.0%, P=0.044;81.6% vs. 59.1%, P=0.019). Conclusions Radical surgery achieves a good prognosis in patients with stage II/III upper rectal cancer, and postoperative CRT can further reduce the locoregional recurrence rate. Particularly, postoperative CRT/RT can substantially improve local and long-term outcomes in patients with high-risk factors.
[1] DeSantis CE,Lin CC,Mariotto AB,et al. Cancer treatment and survivorship statistics,2014[J].CA Cancer J Clin,2014,64(4):252-271.DOI:10.3322/caac.21235. [2] 赫捷,陈万青.2012中国肿瘤登记年报[M].北京:军事医学科学出版社,2012. [3] Marijnen CA,Nagtegaal ID,Kapiteijn E,et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients:report of a multicenter randomized trial[J]. Int J Radiat Oncol Biol Phys,2003,55(5):1311-1320. [4] Kapiteijn E,Marijnen CA,Nagtegaal ID,et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer[J]. N Engl J Med,2001,345(9):638-646. [5] Birgisson H,Pahlman L,Gunnarsson U,et al. Adverse effects of preoperative radiation therapy for rectal cancer:long-term follow-up of the Swedish rectal cancer trial[J]. J Clin Oncol,2005,23(34):8697-705. [6] Stomach[A]//Edge SB,Byrd DR,Compton CC,et al. AJCC cancer staging manual[M].7th ed. New York:Springer,2010:173-206. [7] Roels S,Duthoy W,Haustermans K,et al. Definition and delineation of the clinical target volume for rectal cancer[J]. Int J Radiat Oncol Biol Phys,2006,65(4):1129-1142. [8] Lopez-Kostner F,Lavery IC,Hool GR,et al. Total mesorectal excision is not necessary for cancers of the upper rectum[J].Surgery,1998,124(4):612-618. [9] Faerden AE,Naimy N,Wiik P,et al. Total mesorectal excision for rectal cancer:difference in outcome for low and high rectal cancer[J]. Dis Colon Rectum,2005,48(12):2224-2231. [10] Folkesson J,Birgisson H,Pahlman L,et al. Swedish rectal cancer trial:long lasting benefits from radiotherapy on survival and local recurrence rate[J]. J Clin Oncol,2005,23(24):5644-5650. [11] Lee SH,de Anda EH,Finne CO,et al. The effect of circumferential tumor location in clinical outcomes of rectal cancer patients treated with total mesorectal excision[J]. Dis Colon Rectum,2005,48(12):2249-2257. [12] Chiang JM,Hsieh PS,Chen JS,et al. Rectal cancer level significantly affects rates and patterns of distant metastases among rectal cancer patients post curative-intent surgery without neoadjuvant therapy[J]. World J Surg Oncol,2014,12:197.DOI:10.1186/1477-7819-12-197. [13] Lee JL,Yu CS,Kim TW,et al. Rate of pulmonary metastasis varies with location of rectal cancer in the patients undergoing curative resection[J]. World J Surg,2014,39(3):759-768.DOI:10.1007/s00268-014-2870-y. [14] Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial[J]. N Engl J Med,1997,336(14):980-987. [15] Sauer R,Becker H,Hohenberger W,et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer[J]. N Engl J Med,2004,351(17):1731-40. [16] NCCN guidelines panel. National comprehensive cancer network guidelines in oncology:rectal cancer,2015.Version 1[DB/OL][2015-01-10].http://www.cnnc.org/professionals/physician_gls/pdf/rectal.pdf. [17] Schoellhammer HF,Gregorian AC,Sarkisyan GG,et al. How important is rigid proctosigmoidoscopy in localizing rectal cancer[J]. Am J Surg,2008,196(6):904-907,908.DOI:10.1016/j.amjsurg.2008.08.005. [18] Bujko K,Nowacki MP,Nasierowska-Guttmejer A,et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer[J]. Br J Surg,2006,93(10):1215-1223. [19] Glimelius B,Tiret E,Cervantes A,et al. Rectal cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J]. Ann Oncol,2013,24 Suppl 6:vi81-88.DOI:10.1093/annonc/mdt240. [20] Peeters KC,van de Velde CJ,Leer JW,et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer:increased bowel dysfunction in irradiated patients-a Dutch colorectal cancer group study[J]. J Clin Oncol,2005,23(25):6199-6206.
2015, Vol. 24 
